GSB Wealth Management LLC Sells 30 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

GSB Wealth Management LLC trimmed its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 2.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,126 shares of the medical research company’s stock after selling 30 shares during the period. GSB Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $649,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Bornite Capital Management LP boosted its holdings in Thermo Fisher Scientific by 50.0% during the first quarter. Bornite Capital Management LP now owns 30,000 shares of the medical research company’s stock valued at $17,719,000 after purchasing an additional 10,000 shares in the last quarter. Fairfield Bush & CO. boosted its holdings in Thermo Fisher Scientific by 1.2% during the first quarter. Fairfield Bush & CO. now owns 2,928 shares of the medical research company’s stock valued at $1,729,000 after purchasing an additional 36 shares in the last quarter. Loomis Sayles & Co. L P boosted its holdings in Thermo Fisher Scientific by 563.5% during the first quarter. Loomis Sayles & Co. L P now owns 19,844 shares of the medical research company’s stock valued at $11,721,000 after purchasing an additional 16,853 shares in the last quarter. Covestor Ltd boosted its holdings in shares of Thermo Fisher Scientific by 60.5% in the 1st quarter. Covestor Ltd now owns 321 shares of the medical research company’s stock worth $190,000 after acquiring an additional 121 shares in the last quarter. Finally, Merit Financial Group LLC boosted its holdings in shares of Thermo Fisher Scientific by 3.6% in the 1st quarter. Merit Financial Group LLC now owns 669 shares of the medical research company’s stock worth $395,000 after acquiring an additional 23 shares in the last quarter. 87.06% of the stock is currently owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, CFO Stephen Williamson sold 14,100 shares of the company’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $550.00, for a total value of $7,755,000.00. Following the completion of the transaction, the chief financial officer now directly owns 27,393 shares of the company’s stock, valued at approximately $15,066,150. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. In related news, CFO Stephen Williamson sold 14,100 shares of the company’s stock in a transaction on Tuesday, August 1st. The shares were sold at an average price of $550.00, for a total value of $7,755,000.00. Following the completion of the transaction, the chief financial officer now directly owns 27,393 shares of the company’s stock, valued at approximately $15,066,150. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 3,000 shares of the company’s stock in a transaction on Wednesday, August 30th. The stock was sold at an average price of $557.77, for a total transaction of $1,673,310.00. Following the completion of the transaction, the executive vice president now directly owns 17,556 shares of the company’s stock, valued at $9,792,210.12. The disclosure for this sale can be found here. Insiders sold a total of 28,700 shares of company stock worth $15,799,270 in the last quarter. Corporate insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $510.90 on Thursday. The firm has a fifty day moving average of $540.56 and a two-hundred day moving average of $542.09. The stock has a market capitalization of $197.18 billion, a price-to-earnings ratio of 34.92, a PEG ratio of 2.51 and a beta of 0.77. Thermo Fisher Scientific Inc. has a 52 week low of $475.77 and a 52 week high of $609.85. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.02 and a current ratio of 1.42.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, July 26th. The medical research company reported $5.15 EPS for the quarter, missing the consensus estimate of $5.43 by ($0.28). Thermo Fisher Scientific had a net margin of 13.14% and a return on equity of 18.59%. The business had revenue of $10.69 billion for the quarter, compared to the consensus estimate of $10.99 billion. During the same quarter in the previous year, the firm posted $5.51 EPS. The business’s revenue was down 2.6% on a year-over-year basis. As a group, equities research analysts predict that Thermo Fisher Scientific Inc. will post 22.37 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 13th. Investors of record on Friday, September 15th will be given a $0.35 dividend. This represents a $1.40 dividend on an annualized basis and a dividend yield of 0.27%. The ex-dividend date of this dividend is Thursday, September 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 9.57%.

Analyst Upgrades and Downgrades

TMO has been the topic of several recent analyst reports. Citigroup initiated coverage on Thermo Fisher Scientific in a report on Wednesday, September 6th. They issued a “buy” rating and a $625.00 target price on the stock. Barclays boosted their target price on Thermo Fisher Scientific from $590.00 to $625.00 and gave the stock an “overweight” rating in a report on Thursday, July 27th. JPMorgan Chase & Co. boosted their price objective on shares of Thermo Fisher Scientific from $660.00 to $670.00 in a research report on Thursday, July 27th. Raymond James boosted their price objective on shares of Thermo Fisher Scientific from $595.00 to $630.00 and gave the stock an “outperform” rating in a research report on Friday, July 28th. Finally, Credit Suisse Group upgraded shares of Thermo Fisher Scientific from a “neutral” rating to an “outperform” rating and set a $620.00 price objective for the company in a research report on Thursday, July 13th. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $631.71.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, clinical next-generation sequencing, bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.